Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Yichen Therapeutics Limited has 3 pending office actions in the Computing & Software technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's software-related intellectual property is being reviewed by multiple examiners in different technical units. The involvement of multiple art units indicates that the software technology spans more than one administrative classification within the patent office.
STCLAIR, ANDREW D is the busiest examiner for the portfolio, managing 2 pending office actions. This examiner handles a larger portion of the company's 3 pending office actions. The remaining action is handled by another distinct examiner. With a concentrated prosecution, particularly with a specific examiner overseeing a significant portion of the active matters, the company may experience more consistent communication regarding its pending software claims.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STCLAIR, ANDREW D | 2 | 60.1% | +25.6% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17261026 | Long-acting fibronectin type III domain fusion protein | STCLAIR, ANDREW D | 488d overdue |
| 17287539 | Bispecific antibody | STCLAIR, ANDREW D | 373d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17261026 | Long-acting fibronectin type III domain fusion protein | STCLAIR, ANDREW D | 488d overdue |
| 17287539 | Bispecific antibody | STCLAIR, ANDREW D | 373d overdue |
| 18686393 | Epitope Modification | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 2178 | 2 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686393 | Epitope Modification | HOLTZMAN, KATHERINE ANN | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 17287539 | Bispecific antibody | STCLAIR, ANDREW D | 2178 | §103§112 | Non-Final OA | 373d overdue | Pending | Apr 22, 2021 |
| 17261026 | Long-acting fibronectin type III domain fusion protein | STCLAIR, ANDREW D | 2178 | §103§112 | Non-Final OA | 488d overdue | Pending | Jan 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYichen Therapeutics Limited has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrew D Stclair has the most, with 2 of Yichen Therapeutics Limited's pending office actions.
Mostly Computing & Software (USPTO Tech Center 2100), based on where its pending office actions are examined.
